BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21524289)

  • 1. Gastrointestinal stromal tumours treated before and after the advent of c-kit immunostaining.
    Sorelli PG; Cohen P; Amo-Takyi B; Theodorou NA; Dawson PM
    World J Surg Oncol; 2011 Apr; 9():44. PubMed ID: 21524289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
    Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A
    Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 5. Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.
    Koay MH; Goh YW; Iacopetta B; Grieu F; Segal A; Sterrett GF; Platten M; Spagnolo DV
    Pathology; 2005 Feb; 37(1):22-31. PubMed ID: 15875730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revision of gastrointestinal mesenchymal tumours with CD117.
    de Schipper JP; Liem RS; van den Ingh HF; van der Harst E
    Eur J Surg Oncol; 2004 Nov; 30(9):959-62. PubMed ID: 15498641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
    Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
    Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.
    Al-Maqrashi Z; Burney IA; Taqi KM; Al-Sawafi Y; Qureshi A; Lakhtakia R; Mehdi I; Al-Bahrani B; Kumar S; Al-Moundhri M
    Sultan Qaboos Univ Med J; 2021 May; 21(2):e237-e243. PubMed ID: 34221471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53.
    Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC
    Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs.
    Agaimy A; Märkl B; Arnholdt H; Wünsch PH; Terracciano LM; Dirnhofer S; Hartmann A; Tornillo L; Bihl MP
    Virchows Arch; 2009 Aug; 455(2):101-8. PubMed ID: 19572146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
    Pauls K; Merkelbach-Bruse S; Thal D; Büttner R; Wardelmann E
    Histopathology; 2005 Feb; 46(2):166-75. PubMed ID: 15693889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of incidental gastrointestinal stromal tumours on patients undergoing resection of upper gastrointestinal neoplasms.
    Chan CH; Cools-Lartigue J; Marcus VA; Feldman LS; Ferri LE
    Can J Surg; 2012 Dec; 55(6):366-70. PubMed ID: 22992402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics of KIT and protein kinase C-δ expression in adenoid cystic carcinoma: comparison with chromophobe renal cell carcinoma and gastrointestinal stromal tumour.
    Park CK; Kim WK; Kim H
    Histopathology; 2017 Oct; 71(4):529-542. PubMed ID: 28561935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.